Journal
JOURNAL OF ZHEJIANG UNIVERSITY-SCIENCE B
Volume 18, Issue 11, Pages 921-933Publisher
ZHEJIANG UNIV PRESS
DOI: 10.1631/jzus.B1600441
Keywords
Prostate cancer; Metabolomics; Nuclear magnetic resonance (NMR); Biomarker
Categories
Funding
- Pudong New Area Health and Family Planning Committee, Shanghai, China [PW2016D-13]
Ask authors/readers for more resources
Prostate cancer (PCa) is the second most common male cancer worldwide and the fifth leading cause of death from cancer in men. Early detection and risk stratification is the most effective way to improve the survival of PCa patients. Current PCa biomarkers lack sufficient sensitivity and specificity to cancer. Metabolite biomarkers are evolving as a new diagnostic tool. This review is aimed to evaluate the potential of metabolite biomarkers for early detection, risk assessment, and monitoring of PCa. Of the 154 identified publications, 27 and 38 were original papers on urine and serum metabolomics, respectively. Nuclear magnetic resonance (NMR) is a promising method for measuring concentrations of metabolites in complex samples with good reproducibility, high sensitivity, and simple sample processing. Especially urine-based NMR metabolomics has the potential to be a cost-efficient method for the early detection of PCa, risk stratification, and monitoring treatment efficacy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available